This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Biramijamal, F. Articles by Hollstein, M. Search for Related Content PubMed PubMed Citation Articles by Biramijamal, F. Articles by Hollstein, M.

Unusual Profile and High Prevalence of p53 Mutations in Esophageal Squamous Cell Carcinomas from Northern Iran¹

Departments of Genetic Alterations in Carcinogenesis [F. B., R. K., M. H.] and Cellular and Molecular Pathology [H-J. G.], German Cancer Research Center, D-69120 Heidelberg, Germany; Biochemistry Department, Faculty of Medical Sciences, Tarbiat Modarres University, Tehran, Iran [A. A.]; and Tehran University of Medical Sciences and Health Services, Tehran, Iran [P. M.]

Over 15,000 human tumor p53 mutations have been recorded in the scientific literature, including over 700 mutations in esophageal tumors. There are no data on p53 mutations in esophageal cancer patients from Iran yet; however, this country experiences one of the highest cancer mortality rates in the world for esophageal squamous cell carcinomas (ESCCs). The causes of this high cancer burden in Iran remain obscure and do not appear to be related to tobacco and alcohol consumption, the two major risk factors identified in Europe and North America. Because molecular analysis of tumors can provide clues to endogenous or environmental factors contributing to high cancer risk, we examined 74 Iranian ESCCs for the presence of mutations in exons 5–8 of the p53 gene by PCR and direct sequencing. Forty-eight of the 74 tumors (65%) had one or more p53 gene point mutations, including 5 patients with two or more mutations and one with a tandem mutation in codon 242. Surprisingly, over one-third of the 54 mutations we identified were transitions at CpG sites (20 of a total of 54 mutations, or 37%), a class of mutation that is significantly less common (16% of mutations) in the compilation of ESCC mutations from other countries (² statistic, P < 0.0002), whereas transversions, which the literature shows to be common in ESCCs from non-Iranian patients, were infrequent in the tumors we examined here. Elevated levels of cyclooxygenase-2 and inducible nitric oxide synthase were observed in 74 and 91%, respectively, of tumors from Tehran as determined by immunohistochemistry, and high COX-2 expression correlated significantly with the presence of a p53 mutation in the tumor. Mediators of the inflammatory response in esophageal mucosa, perhaps in conjunction with specific dietary or cultural practices in Iran, may contribute importantly to the p53 mutation load in Iranian ESCC patients.

This article has been cited by other articles:

				F. Islami, A. Pourshams, D. Nasrollahzadeh, F. Kamangar, S. Fahimi, R. Shakeri, B. Abedi-Ardekani, S. Merat, H. Vahedi, S. Semnani, et al. Tea drinking habits and oesophageal cancer in a high risk area in northern Iran: population based case-control study BMJ, March 26, 2009; 338(mar26_2): b929 - b929. [Abstract] [Full Text] [PDF]

				Z. Liu, M. Hergenhahn, H. H. Schmeiser, G. N. Wogan, A. Hong, and M. Hollstein Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene PNAS, March 2, 2004; 101(9): 2963 - 2968. [Abstract] [Full Text] [PDF]

				K.-T. Kuo, K.-C. Chow, Y.-C. Wu, C.-S. Lin, H.-W. Wang, W.-Y. Li, and L.-S. Wang Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma Ann. Thorac. Surg., September 1, 2003; 76(3): 909 - 914. [Abstract] [Full Text] [PDF]

				O. Gallo, N. Schiavone, L. Papucci, I. Sardi, L. Magnelli, A. Franchi, E. Masini, and S. Capaccioli Down-Regulation of Nitric Oxide Synthase-2 and Cyclooxygenase-2 Pathways by p53 in Squamous Cell Carcinoma Am. J. Pathol., August 1, 2003; 163(2): 723 - 732. [Abstract] [Full Text] [PDF]

				J. Breton, F. Sichel, A. Abbas, J. Marnay, D. Arsene, and M. Lechevrel Simultaneous use of DGGE and DHPLC to screen TP53 mutations in cancers of the esophagus and cardia from a European high incidence area (Lower Normandy, France) Mutagenesis, May 1, 2003; 18(3): 299 - 306. [Abstract] [Full Text] [PDF]

				D.-H. Lee, T. R. O'Connor, and G. P. Pfeifer Oxidative DNA damage induced by copper and hydrogen peroxide promotes CG->TT tandem mutations at methylated CpG dinucleotides in nucleotide excision repair-deficient cells Nucleic Acids Res., August 15, 2002; 30(16): 3566 - 3573. [Abstract] [Full Text] [PDF]

				J. Smeds, P. Berggren, X. Ma, Z. Xu, K. Hemminki, and R. Kumar Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16INK4a and p14ARF ) and p53 genes are major targets for inactivation Carcinogenesis, April 1, 2002; 23(4): 645 - 655. [Abstract] [Full Text] [PDF]

				J.-L. Luo, W.-M. Tong, J.-H. Yoon, M. Hergenhahn, R. Koomagi, Q. Yang, D. Galendo, G. P. Pfeifer, Z.-Q. Wang, and M. Hollstein UV-induced DNA Damage and Mutations in Hupki (Human p53 Knock-in) Mice Recapitulate p53 Hotspot Alterations in Sun-exposed Human Skin Cancer Res., November 1, 2001; 61(22): 8158 - 8163. [Abstract] [Full Text] [PDF]

				E. Fosslien Molecular Pathology of Cyclooxygenase-2 in Cancer-induced Angiogenesis Ann. Clin. Lab. Sci., October 1, 2001; 31(4): 325 - 348. [Abstract] [Full Text] [PDF]